Hao Yu

Dr. Hao Yu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LXLiangliang Xu
Liangliang Xu
CZChang Zou
Chang Zou
SZShanshan Zhang
Shanshan Zhang
TCTimothy Shun Man Chu
Timothy Shun Man Chu
YZYan Zhang
Yan Zhang
FKFeng-Ming Kong
Feng-Ming Kong
The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must involve the systemic tumor immune environment (STIE) which was merely illustrated previously. Here, we aim to review recent advances in single-cell transcriptomics and spatial transcriptomics for the studies of STIE, TIME, and their interactions, which may reveal heterogeneity in immunotherapy responses as well as the dynamic changes essential for the treatment effect. We review the evidence from preclinical and clinical studies related to TIME, STIE, and their significance on overall survival, through different immunomodulatory pathways, such as metabolic and neuro-immunological pathways. We also evaluate the significance of the STIE, TIME, and their interactions as well as changes after local radiotherapy and systemic immunotherapy or combined immunotherapy. We focus our review on the evidence of lung cancer, hepatocellular carcinoma, and nasopharyngeal carcinoma, aiming to reshape STIE and TIME to enhance immunotherapy efficacy.

1 May 2012 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
HYHao Yu
Hao Yu
SCSiping Chen
Siping Chen
PCPing Cao
Ping Cao
Low intensity ultrasonic therapy is always an important research area of ultrasonic medicine. This review concentrates on low intensity ultrasound enhancing bactericidal action of antibiotics against bacteria in vitro and in vivo, including planktonic bacteria, bacterial biofilms, Chlamydia, and bacteria in implants. These literatures show that low intensity ultrasound alone is not effective in killing bacteria, while the combination of low intensity ultrasound and antibiotics is promising. Low intensity ultrasound facilitating antibiotic treatment is still in its infancy, and still requires a great deal of research in order to develop the technology on medical treatment scale.

25 March 2016 in Discover Nano
Verified
Journal Article
Open access
PDF file
XQXiaoPing Qi
XiaoPing Qi
YHYunYe Huang
YunYe Huang
ZLZhongShi Lin
ZhongShi Lin
LXLiang Xu
Liang Xu
HYHao Yu
Hao Yu
In the article, a dual-quantum-dots-labeled (dual-QDs-labeled) lateral flow strip (LFS) method was developed for the simultaneous and rapid quantitative detection of procalcitonin (PCT) and C-reactive protein (CRP) in the blood. Two QD-antibody conjugates with different fluorescence emission spectra were produced and sprayed on the LFS to capture PCT and CRP in the blood. Furthermore, a double antibody sandwich method for PCT and, meanwhile, a competitive inhibition method for CRP were employed in the LFS. For PCT and CRP in serum assayed by the dual-QDs-labeled LFS, their detection sensitivities reached 0.1 and 1 ng/mL, respectively, and their linear quantitative detection ranges were from 0.3 to 200 ng/mL and from 50 to 250 μg/mL, respectively. There was little evidence that the PCT and CRP assays would be interfered with each other. The correlations for testing CRP and PCT in clinical samples were 99.75 and 97.02 %, respectively, between the dual-QDs-labeled LFS we developed and commercial methods. The rapid quantification of PCT and CRP on dual-QDs-labeled LFS is of great clinical value to distinguish inflammation, bacterial infection, or viral infection and to provide guidance for the use of antibiotics or other medicines.

15 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZXZhiyuan Xu
Zhiyuan Xu
LYLi Yang
Li Yang
HYHao Yu
Hao Yu
LGLinlang Guo
Linlang Guo
Background/purpose: Severe lymphopenia during pelvic radiotherapy (RT) predicts poor survival in patients with cervical cancer. However, the risk of severe lymphopenia has not been well predicted. We developed a machine learning model using clinical and dosimetric information to predict grade 4 (G4) lymphopenia during pelvic RT in patients with cervical cancer.Methods: This retrospective study included cervical cancer patients treated with definitive pelvic RT ± induction/concurrent chemotherapy. Clinical information and a set of dosimetric parameters of external beam radiotherapy plan were collected. G4 lymphopenia during RT, which was also referred to as G4 absolute lymphocyte count (ALC) nadir, was defined as ALC nadir <0.2 × 109cells/L during RT according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Elastic-net logistic regression models were constructed for the prediction of G4 lymphopenia during pelvic RT using a repeated cross-validation methodology.Results: A total of 130 patients were eligible, and 43 (33.1%) patients had G4 lymphopenia during RT. On multivariable analysis, G4 ALC nadir was associated with poor overall survival (OS) [hazard ratio (HR), 3.91; 95% confidence interval (CI), 1.34–11.38, p = 0.01]. Seven significant factors [Eastern Cooperative Oncology Group (ECOG) performance score, pre-RT hemoglobin, pre-RT lymphocytes, concurrent chemotherapy, gross tumor volume of regional lymphadenopathy (GTV_N volume), body volume, and maximum dose of planning target volume receiving at least 55 Gy (PTV_5500 Dmax)] were obtained by elastic-net logistic regression models and were included in the final prediction model for G4 ALC nadir. The model’s predicting ability in test set was area under the curve (AUC) = 0.77 and accuracy = 0.76. A nomogram of the final predicting model was constructed.Conclusions: This study developed and validated a comprehensive model integrating clinical and dosimetric parameters by machine learning method, which performed well in predicting G4 lymphopenia during pelvic RT for cervical cancer and will facilitate physicians to identify patients at high risk of G4 lymphopenia who might benefit from modified treatment approaches.

16 October 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MWMenghan Wu
Menghan Wu
PSPeishang Shi
Peishang Shi
JHJianmin Huang
Jianmin Huang
XNXiaomin Ni
Xiaomin Ni
RLRuijia Lai
Ruijia Lai
YZYang Zhang
Yang Zhang
The immunosuppressive tumor microenvironment enables immune evasion through mechanisms beyond canonical immune checkpoints. While phosphatidylserine (PS) externalization coordinates apoptotic clearance under physiological conditions, tumors hijack this mechanism through apoptotic mimicry to subvert antitumor immunity. Here, we identify TMEM16F, a calcium-activated phospholipid scramblase, as a driver of tumor-intrinsic PS externalization. TMEM16F-mediated PS scrambling polarized macrophages to an immunosuppressive M2 phenotype, which promotes TGF-β1 secretion and regulatory T cell expansion to suppress cytotoxic lymphocytes. Genetic ablation of TMEM16F abolished PS exposure, systemically reprogrammed the tumor microenvironment and primary immune organs toward immune activation, and suppressed tumor growth across cancer models. Pharmacological scramblase inhibition produced these effects, demonstrating therapeutic potential. Our findings establish TMEM16F-dependent phospholipid scrambling as a critical immune evasion axis and propose targeting this pathway for cancer treatment.

4 December 2025 in Cancer Research
Verified
Journal Article
Closed access
YCYixin Cheng
Yixin Cheng
GHGuanyin Huang
Guanyin Huang
XLXuefei Liu
Xuefei Liu
CWChun Wu
Chun Wu
JLJingru Lian
Jingru Lian
XHXIN HONG
XIN HONG
Intratumoral heterogeneity supports cancer progression and metastasis while limiting therapeutic efficacy. Comprehensive biological characterization of heterogeneous subclones in breast cancer may hold promise in battling against this deadly disease. Using single-cell transcriptomic analysis and in situ profiling of primary tumors, metastases, and circulating tumor cells from multiple patients with breast cancer, we identified a unique EPCAM+ CD68+ TREM2+ tumor subpopulation, likely resulting from the fusion of tumor cells and lipid-associated macrophages (LAM). The presence of these tumor–LAM fusion cells in the blood or in distinct metastatic sites was significantly correlated with metastatic progression. Stable fusion clonal lines established in vitro exhibited substantially enhanced proliferation, tumor initiation, and metastasis formation in mice. Integrative molecular and functional analyses revealed a critical role for SNX10 in mediating tumor–LAM fusion. Mechanistically, SNX10 physically interacted with the phospholipid scramblase ANO6 and maintained its protein stability by suppressing proteasome-mediated degradation. Furthermore, the transcription factor CBX3 directly targeted SNX10 promoter and modulated its expression. Fusion cells accumulated abundant intracellular lipid droplets and were highly sensitive to simvastatin treatment in vitro and in vivo. Together, this study uncovered that CBX3–SNX10–ANO6 signaling facilitates generation of an aggressive tumor-LAM fusion cell subpopulation that promotes metastasis, revealing an alternative metastatic mechanism and exposing putative therapeutic vulnerabilities. Significance: Single-cell transcriptomic profiling combined with functional and clinical validation identifies fusion of tumor cells and lipid-associated macrophages mediated by the CBX3–SNX10–ANO6 axis as a potentially targetable mechanism driving cancer metastasis.